All In MedTech

Device Trial Radar · NCT04660344

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 761 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

761

Actual

Start

May 3, 2021

Primary completion

Jun 15, 2025

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheNot on our public-company list
Sponsor type
Industry
Collaborators
Natera, Inc.
First posted
Dec 9, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.

Conditions

  • Muscle-invasive Bladder Cancer

Interventions

  • AtezolizumabDrug

    ctDNA positive participants will receive 1680 mg IV, every 4 weeks (Q4W) on Day 1 of each 28-day cycle.

  • PlaceboOther

    ctDNA positive participants will receive placebo IV, Q4W on Day 1 of each 28-day cycle

  • SignateraDevice

    Signatera will be used to evaluate whether ctDNA is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. INV-assessed Disease-free Survival (DFS)Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)

Locations

140 sites in 23 countries. Site status is shown where the registry gives one.

  • Cancer Care Centers of Brevard

    Rockledge, Florida

  • Cleveland Clinic

    Cleveland, Ohio

  • AHN Cancer Institute ? Allegheny General Hospital

    Pittsburgh, Pennsylvania

137 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.